BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
(World News Science)

BioMarin InvestorRoom BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition More than 1,300 Patients Treated with Vimizim in Over 50 Countries SAN RAFAEL, Calif., June 4, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition. In May 2018, the...